Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843657 | 0.91 | CYP3A4 (0.43) | ANO1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL16133799 | 0.89 | CYP3A4 (0.40) | ANO1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL16113652 | 0.89 | CYP3A4 (0.40) | ANO1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL16113650 | 0.89 | CYP3A4 (0.40) | ANO1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL2837514 | 0.87 | ANO1 (0.46) | ANO1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL3399393 | 0.86 | ANO1 (0.43) | ANO1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL2836525 | 0.86 | ANO1 (0.43) | ANO1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL2839887 | 0.84 | TUBB4A (0.48) | ANO1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL2840735 | 0.84 | CYP3A4 (0.48) | ANO1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL3540155 | 0.83 | CYP3A4 (0.44) | ANO1CYP3A4CYP2C9CYP2C19CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-28 | — | — | US | disclosed |
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, GOT1 | ANO1 1798/4885CYP3A4 152/4885CYP2C9 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.